The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options.
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression,including in patients with PD-L1 CPS<5.
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression,including in patients with PD-L1 CPS<5.
SHANGHAI,May 24,2024-- Xiao-I Corporation (NASDAQ: AIXI) ("Xiao-I" or the "Company"),a leading AI company announces an important partnership with a major Chinese banking institutio
TORONTO,May 24,2024-- Visionary Holdings Inc. ("we",or the "Company") (NASDAQ: GV),a private education provider with technology of artificial intelligence and life science on the c
In its first year of service,Air Premia\'s Incheon-New York route has quickly established itself as a preferred choice for travelers. To celebrate this milestone,Air Premia is offering a limited time
